Congress orders study on using drug prices to boost domestic pharma
S. 5297 — American Pharmaceutical Security Act · Filed by Adam Schiff (D-CA) · 1 cosponsor · Introduced Aug 6, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Centers for Medicare & Medicaid Services (CMS) to study and report on how it could use its power to set drug prices and coverage rules to boost domestic production of pharmaceutical ingredients and reduce U.S. reliance on foreign suppliers. The report may recommend price floors to protect domestic manufacturers and prioritizing U.S.-made ingredients in Medicare/Medicaid coverage decisions.
Why we flagged it
The bill is a directive for a single report on how CMS could use its pricing and coverage authority to support domestic pharmaceutical manufacturing. It is not a direct mandate or appropriation, but a study that may inform future policy.
What the text implies
- If CMS implements price floors based on this report, Medicare/Medicaid reimbursement rates could rise, increasing federal drug spending and potentially shifting costs to beneficiaries through higher copays or reduced coverage.
- Domestic-source prioritization in Medicare/Medicaid could reduce competition from lower-cost foreign suppliers, potentially raising drug prices for all payers, not just government programs.
The full analysis lists 5 implications of this text.
Who stands to gain
domestic pharmaceutical manufacturers; active pharmaceutical ingredient (API) producers in the United States; contract manufacturers of key starting materials